HC Wainwright Raises BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target to $60.00

BioMarin Pharmaceutical (NASDAQ:BMRN) had its price target upped by equities research analysts at HC Wainwright from $50.00 to $60.00 in a report issued on Friday,Benzinga reports. The brokerage currently has a “neutral” rating on the biotechnology company’s stock. HC Wainwright’s price target would suggest a potential downside of 2.38% from the company’s current price.

Other analysts also recently issued research reports about the stock. Oppenheimer reaffirmed an “outperform” rating on shares of BioMarin Pharmaceutical in a research report on Friday. Sanford C. Bernstein dropped their price target on shares of BioMarin Pharmaceutical from $94.00 to $82.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 5th. The Goldman Sachs Group assumed coverage on BioMarin Pharmaceutical in a report on Monday, May 11th. They set a “neutral” rating and a $69.00 price objective for the company. Weiss Ratings upgraded BioMarin Pharmaceutical from a “sell (d+)” rating to a “hold (c-)” rating in a report on Friday, June 26th. Finally, UBS Group reiterated a “neutral” rating on shares of BioMarin Pharmaceutical in a report on Tuesday, July 14th. One analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and eight have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $87.55.

BioMarin Pharmaceutical Stock Up 2.6%

Shares of NASDAQ:BMRN opened at $61.46 on Friday. The firm has a market cap of $11.88 billion, a P/E ratio of 44.86, a P/E/G ratio of 0.46 and a beta of 0.24. BioMarin Pharmaceutical has a 12-month low of $49.26 and a 12-month high of $66.28. The business has a fifty day simple moving average of $58.06 and a 200 day simple moving average of $57.01. The company has a quick ratio of 4.20, a current ratio of 5.81 and a debt-to-equity ratio of 0.23.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its quarterly earnings results on Thursday, August 6th. The biotechnology company reported $1.20 earnings per share for the quarter, beating the consensus estimate of $0.95 by $0.25. BioMarin Pharmaceutical had a return on equity of 6.50% and a net margin of 8.29%.The company had revenue of $989.71 million during the quarter, compared to analysts’ expectations of $932.03 million. During the same quarter in the prior year, the firm posted $1.44 earnings per share. The business’s quarterly revenue was up 20.0% on a year-over-year basis. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. Analysts predict that BioMarin Pharmaceutical will post 4.22 earnings per share for the current year.

Institutional Investors Weigh In On BioMarin Pharmaceutical

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. CIBC Private Wealth Group LLC raised its position in shares of BioMarin Pharmaceutical by 38.2% in the fourth quarter. CIBC Private Wealth Group LLC now owns 648 shares of the biotechnology company’s stock worth $39,000 after acquiring an additional 179 shares during the period. Northwestern Mutual Investment Management Company LLC grew its position in shares of BioMarin Pharmaceutical by 0.4% during the 4th quarter. Northwestern Mutual Investment Management Company LLC now owns 42,982 shares of the biotechnology company’s stock valued at $2,554,000 after acquiring an additional 183 shares during the period. Caerus Investment Advisors LLC increased its stake in shares of BioMarin Pharmaceutical by 2.8% in the 4th quarter. Caerus Investment Advisors LLC now owns 10,236 shares of the biotechnology company’s stock valued at $608,000 after purchasing an additional 278 shares in the last quarter. Chicago Partners Investment Group LLC increased its stake in shares of BioMarin Pharmaceutical by 2.4% in the 1st quarter. Chicago Partners Investment Group LLC now owns 12,183 shares of the biotechnology company’s stock valued at $660,000 after purchasing an additional 290 shares in the last quarter. Finally, Parallel Advisors LLC raised its holdings in BioMarin Pharmaceutical by 62.2% in the 3rd quarter. Parallel Advisors LLC now owns 769 shares of the biotechnology company’s stock worth $42,000 after purchasing an additional 295 shares during the period. 98.71% of the stock is currently owned by institutional investors.

Key Headlines Impacting BioMarin Pharmaceutical

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: BioMarin reported second-quarter adjusted earnings of $1.20 per share, exceeding the $0.95–$0.96 analyst consensus. Revenue rose 20% year over year to approximately $990 million, well above expectations of roughly $932 million. BioMarin Reports Second Quarter 2026 Financial and Operating Results
• Positive Sentiment: The company raised its full-year 2026 adjusted diluted EPS guidance to $4.90–$5.10, above the prior analyst consensus of about $4.80. Management also cited stronger growth expectations for total revenue and VOXZOGO. BioMarin Pharmaceutical Surpasses Q2 Earnings and Revenue Estimates
• Positive Sentiment: Management said the addition of GALAFOLD and POMBILITI plus OPFOLDA, together with expected cost synergies, should accelerate revenue growth, improve EPS, expand operating margins and increase operating cash flow through the mid-2030s. BioMarin Q2 2026 Earnings Call Transcript
• Negative Sentiment: Despite the earnings beat, quarterly EPS declined from $1.44 in the year-earlier period to $1.20, which may temper enthusiasm about near-term profitability. Full-year revenue guidance of approximately $3.9 billion was broadly in line with consensus rather than a major upside surprise. Compared to Estimates, BioMarin Q2 Earnings: A Look at Key Metrics

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.